Recombinetics Inc. Completes Joint Venture Transaction with Makana Therapeutics

Recombinetics Inc. formed a joint venture with Makana Therapeutics to develop organs in pigs, or other animals, for transplantation into human patients, which is known as xenotransplantation. Faegre Drinker represented Recombinetics in the deal, which effectively brought together technologies and expertise held by the two participants to accelerate the field of xenotransplantation.

Results may vary depending on your particular facts and legal circumstances.